LMRI

Rating buyAI Memo

Lumexa Imaging

As of 2026-07-27/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-27 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

6‑12m

Key catalyst

2026 guidance delivery • 2026-12-31

Base target: $12 / p=57% prob

Biggest risk

Revenue growth was modest at 3.1% year over year and adjusted EBITDA was nearly flat at $51.2 million versus $51.0 million, leaving execution, ramp-up, and earnings conversion as open questions.

Invalidation

Break below $8 or thesis failure.

What would change my mind?

Q1 advanced-imaging volume growth and the reiterated 2026 outlook support a constructive long-term case, with center additions providing potential incremental capacity [#SEC-8K-2026-05-12].

Research note

Recommendation

buy

Confidence

medium

As of

2026-07-27

Base target

$12

p=57%

Bull target

$17

p=18%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Advanced-imaging volume execution
Center expansion and ramp-up
Q1 advanced-imaging volume growth and the reiterated 2026 outlook support a constructive long-term case, with center additions providing potential incremental capacity [#SEC-8K-2026-05-12].

BearKey bullets

Analyst revision breadth, options data, short interest, and social sentiment are unavailable.
Cash generation, leverage management, and balance-sheet validation remain incomplete in the available packet.
De novo and tuck-in center execution may be slower or less profitable than expected.

WatchKey bullets

2026 guidance delivery

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $12 (p=57%)

Target spread vs base: +50% / -29%

Scenario probabilities

Bull Target: $17 (p=18%)Base Target: $12 (p=57%)Bear Target: $8 (p=25%)

Commentary

News tone is modestly constructive around Q1 growth and reiterated guidance, but coverage is narrow. Social, options, short-interest, employee-sentiment, and analyst-revision data are unavailable; their absence is not positive evidence. The appropriate stance is a cautious monitoring long.

As of 2026-07-27 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Q1 advanced-imaging volume growth and the reiterated 2026 outlook support a constructive long-term case, with center additions providing potential incremental capacity [#SEC-8K-2026-05-12].

Bear Case

Revenue growth was modest at 3.1% year over year and adjusted EBITDA was nearly flat at $51.2 million versus $51.0 million, leaving execution, ramp-up, and earnings conversion as open questions.

Drivers

Scannable catalysts and supporting factors

Advanced-imaging volume execution
Center expansion and ramp-up

Scenarios

Bull Target (Scenario probability)

$17 / p=18% prob

Base Target (Scenario probability)

$12 / p=57% prob

Bear Target (Scenario probability)

$8 / p=25% prob

Analysis 2026-07-27 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.55

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
2026 guidance delivery
The company reiterated 2026 guidance of $1.045–$1.097 billion revenue, $234–$242 million adjusted EBITDA, and $0.71–$0.77 adjusted EPS. Delivery against this range is the key forward validation point [#SEC-8K-2026-05-12].
Prob 60.00% • Move 8.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Advanced-imaging volume execution
2026-12-31
Q1 consolidated same-center advanced volume grew 5.6%, while advanced procedures increased 6.8% year over year. Sustained volume and mix improvement is the clearest operating support for the 2026 outlook [#SEC-8K-2026-05-12].
Prob 65% • Move 12% • Priced-in 45%
Center expansion and ramp-up
2026-12-31
Management announced four additional centers, including two tuck-in acquisitions and two de novos, and reiterated its goal of adding 8–10 de novo centers in 2026. Financial contribution and ramp speed remain unproven [#SEC-8K-2026-05-12].
Prob 58% • Move 13% • Priced-in 35%

Risks

Analyst revision breadth, options data, short interest, and social sentiment are unavailable.
Cash generation, leverage management, and balance-sheet validation remain incomplete in the available packet.
De novo and tuck-in center execution may be slower or less profitable than expected.
Modest Q1 revenue growth and nearly flat adjusted EBITDA leave limited evidence of operating leverage.

Peers

Symbol	Summary
BVS	Similar-market-cap health-care equipment/services comparator; direct operating overlap with outpatient imaging is not established in the packet.
DRTS	Similar-market-cap health-care equipment/services comparator, but business overlap with Lumexa's outpatient imaging model is limited.
ABT	Large diversified medtech comparator with substantially different scale, diversification, and balance-sheet characteristics; direct read-through is limited.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-27

Loading AI feed…

Symbol

Summary

BVS

Similar-market-cap health-care equipment/services comparator; direct operating overlap with outpatient imaging is not established in the packet.

DRTS

Similar-market-cap health-care equipment/services comparator, but business overlap with Lumexa's outpatient imaging model is limited.

ABT

Large diversified medtech comparator with substantially different scale, diversification, and balance-sheet characteristics; direct read-through is limited.